Evidence map›Paper›PMID 41892177›Full record

Trial reportCurrent oncology (Toronto, Ont.)2026

Higher Dose Irradiation for Malignant Spinal Cord Compression: Long-Term Results of the RAMSES-01 Trial.

Dirk Rades, Darejan Lomidze, Natalia Jankarashvili, Fernando Lopez Campos, Arturo Navarro-Martin, Barbara Segedin, Blaz Groselj, Charlotte Kristiansen, Kristopher Dennis, Jon Cacicedo

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dirk RadesDepartment of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.ORCID 0009-0008-2046-4968
Darejan LomidzeRadiation Oncology Department, Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi 0177, Georgia.
Natalia JankarashviliDepartment of Radiation Oncology, Acad. F. Todua Medical Center-Research Institute of Clinical Medicine, Tbilisi 0112, Georgia.
Fernando Lopez CamposDepartment of Radiation Oncology, University Hospital Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-4077-0507
Arturo Navarro-MartinDepartment of Radiation Oncology, Clínic Barcelona Villarroel 170, 08036 Barcelona, Spain.ORCID 0000-0002-1327-5367
Barbara SegedinDepartment of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0003-0309-6282
Blaz GroseljDepartment of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0003-4799-2978
Charlotte KristiansenDepartment of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.ORCID 0000-0002-8073-5781
Kristopher DennisDivision of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, ON K1Y 4E9, Canada.ORCID 0000-0002-5588-1007
Jon CacicedoDepartment of Radiation Oncology, Cruces University Hospital/Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the increasing popularity of upfront decompressive surgery, there are still patients with malignant spinal cord compression (MSCC) and expected longer-term survival receiving irradiation alone. In these patients, local progression-free survival (LPFS) may be improved with doses beyond the commonly applied regimen of 10 × 3.0 Gy. A prospective phase 2 trial (RAMSES-01) investigated the benefit of two regimens, 15 × 2.633 and 18 × 2.333 Gy, compared with a 10 × 3.0 Gy (historical control). Patients in the phase 2 cohort had significantly better local progression-free survival (LPFS) after 1 year. Since recurrent MSCC-related motor weakness is a serious situation, it must be avoided as long as possible. In this respect, it is important to know whether the superiority of 15 × 2.633 and 18 × 2.333 Gy found in the RAMSES-01 trial still exists after 2 or 3 years. This led to the current study. In the phase 2 group, 2- and 3-year LPFS rates were 93.1% and 93.1%, respectively, and survival rates were 54.2% and 36.1%, respectively. According to propensity-adjusted Cox regression analyses, radiotherapy regimens in the phase 2 cohort resulted in significantly better LPFS at 2 (

Indexed as

Spinal Cord CompressionAgedFemaleHumansMaleMiddle AgedProspective StudiesRadiotherapy Dosagehighly-conformal irradiationlocal progression-free survivallong-term resultsmalignant spinal cord compressionpropensity-score adjustment

Identifiers

PMID41892177
PMCPMC13025722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.